MCID: SLV012
MIFTS: 42

Salivary Gland Adenoid Cystic Carcinoma malady

Categories: Rare diseases, Cancer diseases, Oral diseases, Skin diseases, Endocrine diseases

Aliases & Classifications for Salivary Gland Adenoid Cystic Carcinoma

About this section

Aliases & Descriptions for Salivary Gland Adenoid Cystic Carcinoma:

Name: Salivary Gland Adenoid Cystic Carcinoma 10 47 12
Adenoid Cystic Carcinoma 10 45 65
Cylindroma 10 45
Adenoid Cystic Carcinoma of Salivary Gland 65
Carcinoma, Adenoid Cystic 36
Eccrine Dermal Cylindroma 65
 
Carcinoma Adenoid Cystic 47
Adenoid Cystic Cancer 10
Adenocystic Carcinoma 45
Carcinoma, Cribriform 65
Cribriform Carcinoma 45
Cylindroma Nos 10

Classifications:



External Ids:

Disease Ontology10 DOID:4866
MeSH36 D003528
NCIt42 C2970
UMLS65 C0010606, C0279751, C1305968

Summaries for Salivary Gland Adenoid Cystic Carcinoma

About this section
NIH Rare Diseases:45 Adenoid cystic carcinoma (acc) is a rare form of adenocarcinoma, which is cancer that begins in gladular tissues. acc most commonly arises in the head and neck, in various parts of the major and minor salivary glands including the palate, nasopharynx, lining of the mouth, voice box (larynx) or windpipe (trachea). it can also occur in the breast, uterus, or other locations in the body. early symptoms depend on the tumor's location and may include lumps under the lining of the mouth or facial skin; numbness in the mouth or face; difficulty swallowing; hoarseness; pain; or paralysis of a facial nerve. acc often has long periods with no growth followed by growth spurts; however, it can be aggressive in some people. acc spreads along nerves or through the bloodstream, and only spreads to the lymph nodes in about 5-10% of cases. the cause of acc is currently unknown. treatment depends on many factors and may include surgery, radiation, and/or chemotherapy. last updated: 12/10/2014

MalaCards based summary: Salivary Gland Adenoid Cystic Carcinoma, also known as adenoid cystic carcinoma, is related to esophageal adenoid cystic carcinoma and rhinitis. An important gene associated with Salivary Gland Adenoid Cystic Carcinoma is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways are E-cadherin signaling in the nascent adherens junction and Dendritic Cells Developmental Lineage Pathway. Affiliated tissues include salivary gland, skin and breast, and related mouse phenotypes are craniofacial and limbs/digits/tail.

Disease Ontology:10 A salivary gland carcinoma that is characterized by a distinctive pattern in which abnormal nests or cords of epithelial cells surround and/or infiltrate ducts or glandular structures within the affected organ. These structures are typically filled with a mucous-like material or contain abnormal fibrous membranes.

Related Diseases for Salivary Gland Adenoid Cystic Carcinoma

About this section

Diseases related to Salivary Gland Adenoid Cystic Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 164)
idRelated DiseaseScoreTop Affiliating Genes
1esophageal adenoid cystic carcinoma34.1KIT, PGR
2rhinitis30.8KIT, PCNA
3cervical adenoid cystic carcinoma30.3AQP1, BCL2, CDH1, CTTN, CYLD, EN1
4breast cancer28.5BCL2, CDH1, CTTN, KIT, PCNA, PGR
5prostate adenoid cystic carcinoma12.6
6lung adenoid cystic carcinoma12.6
7trachea adenoid cystic carcinoma12.6
8maxillary sinus adenoid cystic carcinoma12.6
9ethmoid sinus adenoid cystic carcinoma12.6
10lacrimal gland adenoid cystic carcinoma12.6
11laryngeal adenoid cystic carcinoma12.6
12breast adenoid cystic carcinoma12.6
13bartholin's gland adenoid cystic carcinoma12.6
14parotid gland adenoid cystic carcinoma12.6
15adenoid cystic carcinoma of the corpus uteri12.6
16cribriform carcinoma12.5
17cutaneous adenocystic carcinoma12.5
18adnexal spiradenoma/cylindroma of a sweat gland12.3
19malignant cylindroma12.3
20poncet-spiegler's cylindroma12.3
21cylindromatosis, familial12.0
22brooke-spiegler syndrome11.9
23lymph node adenoid cystic carcinoma11.5
24urethral verrucous carcinoma10.5CDH1, RUNX3
25ganglion or cyst of synovium/tendon/bursa10.4NOS2, VEGFA
26teratoma10.4
27salpingitis10.4KIT, NOS2
28common bile duct neoplasm10.4CDH1, VEGFA
29oral lichen planus10.3NOS2, PCNA
30neuronitis10.3
31immature cataract10.3AQP1, VEGFA
32caroli disease10.3BCL2, KIT
33soft tissue sarcoma childhood10.3BCL2, VEGFA
34uterine ligament serous adenocarcinoma10.3BCL2, VEGFA
35pachyonychia congenita 310.3
36pachyonychia congenita 410.3
37pachyonychia congenita 110.3
38pachyonychia congenita 210.3
39ceruminous carcinoma10.3
40microinvasive gastric cancer10.3PCNA, VEGFA
41mediastinum synovial sarcoma10.3BCL2, KIT
42locked-in syndrome10.3AQP1, PCNA
43systemic lupus erythematosus10.2
44hiv-110.2
45aspergillosis10.2
46retinoblastoma10.2
47tyrosinemia, type i10.2
48amelogenesis imperfecta10.2
49congestive heart failure10.2
50hemolytic anemia10.2

Graphical network of the top 20 diseases related to Salivary Gland Adenoid Cystic Carcinoma:



Diseases related to salivary gland adenoid cystic carcinoma

Symptoms for Salivary Gland Adenoid Cystic Carcinoma

About this section

Drugs & Therapeutics for Salivary Gland Adenoid Cystic Carcinoma

About this section

Drugs for Salivary Gland Adenoid Cystic Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 156)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
FluconazoleapprovedPhase 2, Phase 317186386-73-43365
Synonyms:
2,4-Difluoro-alpha,alpha-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol
2,4-difluoro-,1-bis(1H-1,2,4-triazol-1-ylmethyl)benzyl alcohol
2-(2,4-DIFLUOROPHENYL)-1,3-DI(1H-1,2,4-TRIAZOL-1-YL)PROPAN-2-OL
2-(2,4-DIFLUOROPHENYL)-1,3-di(1H-1,2,4-triazol-1-yl)propan-2-ol
2-(2,4-Difluoro-phenyl)-1,3-bis-[1,2,4]triazol-1-yl-propan-2-ol
2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)-2-propanol
2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol
2-(2,4-Difluorophenyl)-1,3-di-1H-1,2,4-triazol-1-ylpropan-2-ol
2-(2,4-difluorophenyl)-1,3-bis(1,2,4-triazol-1-yl)propan-2-ol
86386-73-4
AC-428
AC1L1FRQ
AC1Q77FV
AKOS000280854
AbZ Brand of Fluconazole
Afungil
Alflucoz
Aliud Brand of Fluconazole
Alpharma Brand of Fluconazole
Apo Fluconazole
Apo-Fluconazole
Apotex Brand of Fluconazole
Armstrong Brand of Fluconazole
BIDD:GT0799
BRD-K05977355-001-02-6
BSPBio_003504
Baten
Beagyne
Bio-0041
Biocanol
Biozole
Biozolene
C13H12F2N6O
CCRIS 7211
CHEBI:46081
CHEMBL106
CID3365
CPD000471882
Canesoral
Canzol
Chemia Brand of Fluconazole
Cryptal
D00322
D015725
DB00196
DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER
DIFLUCAN IN SODIUM CHLORIDE 0.9%
DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
DRG-0005
Diflazon
Diflucan
Diflucan (TN)
Diflucan, Trican, Alfumet, Fluconazole
Dimycon
DivK1c_001030
Effik Brand of Fluconazole
Elazor
F0677
F8929_SIGMA
FCZ
FLCZ
Fluc Hexal
Flucazol
FlucoLich
Flucobeta
Fluconazol
Fluconazol AL
Fluconazol AbZ
Fluconazol Isis
Fluconazol Stada
Fluconazol [Spanish]
Fluconazol ratiopharm
Fluconazol von ct
Fluconazol-Isis
Fluconazol-ratiopharm
Fluconazole
Fluconazole & Bovine Lactoferrin
Fluconazole & Human recombinant granulocyte colony stimulating factor
Fluconazole & MC-510,011
Fluconazole & hGCSF
Fluconazole (JAN/USAN/INN)
Fluconazole [USAN:INN:BAN:JAN]
Fluconazole in combination with MGCD290
Fluconazole in dextrose 5% in plastic container
Fluconazole in sodium chloride 0.9%
Fluconazole in sodium chloride 0.9% in plastic container
Fluconazolum
Fluconazolum [Latin]
Flucostat
 
Flucytosine & Nyotran
Flucytosine & Nyotran(Liposomal Nystatin)
Flukezol
Flunazul
Flunizol
Fluzone
Forcan
Fuconal
Fungata
GL663142 & Fluconazole
HMS1922O10
HMS2090I20
HMS2093M21
HMS503M21
HSDB 7420
Hexal Brand of Fluconazole
I06-0069
IDI1_001030
KBio1_001030
KBio2_002134
KBio2_004702
KBio2_007270
KBio3_003009
KBioGR_000360
KBioSS_002134
KS-1059
LS-1858
Lavisa
Lesvi Brand of Fluconazole
Lichtenstein Brand of Fluconazole
Loitin
MLS001066394
MLS001165780
MLS001195645
MLS001304713
MLS001306492
Mack Brand of Fluconazole
MolPort-000-883-859
MolPort-002-885-825
Monicure
Mutum
NCGC00095089-01
NCGC00095089-02
NCGC00095089-04
NCGC00095089-05
NINDS_001030
Neofomiral
Oxifugol
Oxifungol
Pfizer Brand of Fluconazole
Pfleger Brand of Fluconazole
Pritenzol
S1331_Selleck
SAM002589905
SAT Brand of Fluconazole
SMR000471882
SPBio_001613
SPECTRUM1503975
STK619301
Silanes Brand of Fluconazole
Solacap
Spectrum2_001607
Spectrum3_001912
Spectrum4_000090
Spectrum5_001277
Spectrum_001654
Stada Brand of Fluconazole
Syscan
TL8005609
TPF
Triflucan
UK 49858
UK-49858
UK49858
UNII-8VZV102JFY
Vita Brand of Fluconazole
XMP.284 & Fluconazole
XMP.366 & Fluconazole
XMP.391 & Fluconazole
ZINC00004009
Zemyc
Zoltec
Zonal
betapharm Brand of Fluconazole
ct Arzneimittel Brand of Fluconazole
ct-Arzneimittel Brand of Fluconazole
fluconazole
nchembio.100-comp3
nchembio.65-comp15
ratiopharm Brand of Fluconazole
2
Megestrol acetateapprovedPhase 360595-33-511683
Synonyms:
17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione
17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione 17-acetate
17alpha-Acetoxy-6-dehydro-6-methylprogesterone
17alpha-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate
17α-Acetoxy-6-dehydro-6-methylprogesterone
17α-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate
6-Dehydro-6-methyl-17alpha-acetoxyprogesterone
6-Dehydro-6-methyl-17α-acetoxyprogesterone
6-Methyl-17alpha-acetoxypregna-4,6-diene-3,20-dione
6-Methyl-17alpha-hydroxy-delta(sup 6)-progesterone acetate
6-Methyl-17α-acetoxypregna-4,6-diene-3,20-dione
6-Methyl-17α-hydroxy-delta(sup 6)-progesterone acetate
6-Methyl-6-dehydro-17alpha-acetoxyprogesterone
6-Methyl-6-dehydro-17α-acetoxyprogesterone
6-Methyl-delta(sup 4,6)-pregnadien-17alpha-ol-3,20-dione acetate
6-Methyl-delta(sup 4,6)-pregnadien-17α-ol-3,20-dione acetate
 
6-Methyl-delta(sup 6)-dehydro-17alpha-acetoxyprogesterone
6-Methyl-delta(sup 6)-dehydro-17α-acetoxyprogesterone
MGA
Magestin
Maygace
Megace
Megace Es
Megeron
Megestat
Megestil
Megestin
Megestol
Megestrol
Megestrol Acetate
Niagestin
Ovaban
Ovarid
Volidan
3
CevimelineapprovedPhase 35107233-08-983898, 25137844
Synonyms:
(+-)-cis-2-Methylspiro(1,3-oxathiolane-5,3'-quinuclidine) hydrochloride, hemihydrate
(+/-)cis-2-methylspiro(1-azabicyclo[2.2.2]octance-3,5'-(1,3)oxathiolane) hydrochloride hemihydrate
(2R,2'R)-2'-methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] dihydrochloride hydrate
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane]
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] dihydrate hydrochloride
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate dihydrochloride
(2R,5R)-2-methylspiro[1,3-oxathiolane-5,3'-1-azabicyclo[2.2.2]octane] hydrate hydrochloride
107233-08-9
153504-70-2
2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine
AC1L36EF
AC1L36GD
AC1NR4MS
AC1OCEXD
AF 102B
AF-102B
AF102B
BIDD:GT0265
C10H17NOS
CHEMBL1200362
CID5284532
CID6918023
CID83898
CID83927
Cevimelina
Cevimeline
Cevimeline (INN)
Cevimeline HCl 1/2H2O
Cevimeline Hydrochloride
 
Cevimeline [INN]
Cevimeline hydrochloride
Cevimeline hydrochloride (USAN)
Cevimeline hydrochloride [USAN]
Cevimeline hydrochloride hemihydrate
Cevimeline hydrochloride hydrate
Cevimeline hydrochloride hydrate (JAN)
Cevimeline.HCl
Cevimelinum
D00661
D07667
DB00185
Evoxac
Evoxac (TN)
FKS-508
Fks 508
HSDB 7286
LS-145782
LS-172037
NCGC00181793-01
SND 5008, AF-102B, FKS-508
SND-5008
SNI-2011
SNK-508
Saligren
Saligren (TN)
Sni 2011
UNII-K9V0CDQ56E
UNII-P81Q6V85NP
cevimeline hydrochloride hydrate
cis-2-Methylspiro(1,3-oxathiolane-5,3')quinuclidine hydrochloride hydrate (2:2:1)
4
Miconazoleapproved, investigationalPhase 2, Phase 3, Phase 1302622916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
Desenex
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Makesense
Micantin (nitrate)
Micatin
 
Miconasil Nitrate
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Oravig
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
Rash Relief Antifungal
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
5
Fentanylapproved, illicit, investigationalPhase 3705437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Abstral
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl - Novaplus
Fentanyl Citrate
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
 
Fentanyl-12
Fentanyl-25
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Lazanda
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
Subsys
UNII-UF599785JZ
fentanyl
6
DoxepinapprovedPhase 3131668-19-5667477, 667468
Synonyms:
(3E)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine
(3E)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine
(3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-di(methyl)propan-1-amine
(3Z)-3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine
(3Z)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine
(Z)-Doxepin
11-(3-(Dimethylamino)propylidene)-6H-dibenz(b,e)oxepine
11-(3-Dimethylamino-propyliden)-6,11-dihydro-dibenz(b,e)oxipin
11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenz(b,e)oxipin
1668-19-5
3-(6H-benzo[c][1]benzoxepin-11-ylidene)-N,N-dimethylpropan-1-amine
3-Dibenz[b,e]oxepin-11(6H)-ylidene-N,N-dimethyl-1-propanamine
3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine
3607-18-9
AC1L1FAW
AC1LDI5F
AC1LDI63
AC1NUW4A
AKOS001582771
Adapin
Aponal
BPBio1_000118
BRD-K36616567-003-01-5
BRD-K37694030-003-02-8
BRD-K54462405-003-03-3
BSPBio_000106
BSPBio_001934
C06971
C19H21NO
CAS-1229-29-4
CCRIS 9176
CHEBI:36691
CHEBI:36692
CHEBI:4710
CHEMBL101740
CID10039438
CID3158
CID5462131
CID667468
CID667477
Cidoxepin
Cidoxepin [INN]
Cidoxepina
Cidoxepinum
Curatin
D07875
DB01142
DivK1c_000431
Doxepin
Doxepin (INN)
Doxepin (Z)-isomer
Doxepin Hcl
Doxepin Hydrochloride
Doxepin Hydrochloride,
Doxepin [USAN]
 
Doxepin, Hydrochloride
Doxepina
Doxepina [INN-Spanish]
Doxepine
Doxepinum
Doxepinum [INN-Latin]
HSDB 3069
IDI1_000431
KBio1_000431
KBio2_001285
KBio2_003853
KBio2_006421
KBio3_001154
KBioGR_001131
KBioSS_001285
L000699
LS-174582
LS-61638
Lopac-D-4526
Lopac0_000339
MF 10
MOLI001594
MolPort-003-847-024
MolPort-005-933-834
N,N-Dimethyldibenz(b,e)oxepin-delta(11(6H),gamma)-propylamine
NCGC00015344-01
NCGC00015344-02
NCGC00015344-04
NCGC00024623-01
NCGC00024623-02
NCGC00162127-01
NINDS_000431
Oprea1_473232
Prestwick0_000263
Prestwick1_000263
Prestwick2_000263
Prestwick3_000263
Prudoxin
Quitaxon
SPBio_000206
SPBio_002325
Silenor
Sinequan
Sinequan (TN)
Spectrum2_000133
Spectrum3_000407
Spectrum4_000526
Spectrum5_001051
Spectrum_000805
Tocris-0508
Triadapin
UNII-5ASJ6HUZ7D
UNII-F96TTB8728
Zonalon
cis-N-(3-(6H-Dibenz(b,e)oxepin-11-yliden)propyl)-N,N-dimethylamin
cis-doxepin
doxepin
7
Histamine PhosphateapprovedPhase 390651-74-165513
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
EINECS 200-118-4
 
H0147
Histamine Positive Skin Test Control
Histamine Positive skin test control
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
Histaminum
LS-78569
UNII-QWB37T4WZZ
8
Docetaxelapproved, investigational, Approved May 1996Phase 3, Phase 2, Phase 11844114977-28-5148124, 9877265
Synonyms:
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
01885_FLUKA
114977-28-5
4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC-383
AC1L3WHJ
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
Docefrez
Docetaxel
Docetaxel (INN)
Docetaxel anhydrous
Docetaxel, Trihydrate
EmDOC
 
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
TXL
Taxotere
Taxotere (TN)
Taxotere(R)
XRP-6976L
docetaxel
docetaxel 114977-28-5
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
9Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 2, Phase 39988
10Cytochrome P-450 CYP2C9 InhibitorsPhase 2, Phase 3497
11Hormone AntagonistsPhase 2, Phase 310002
12Cytochrome P-450 Enzyme InhibitorsPhase 2, Phase 33036
13HormonesPhase 2, Phase 3, Phase 111748
14Contraceptive AgentsPhase 31706
15Antimitotic AgentsPhase 3, Phase 2, Phase 14296
16Tubulin ModulatorsPhase 3, Phase 2, Phase 14279
17Alkylating AgentsPhase 3, Phase 2, Phase 13582
18
MegestrolPhase 3603562-63-819090, 3080587
Synonyms:
(8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-6,10,13-trimethyl-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-3-one
17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione
3562-63-8
AC1L2DG3
C07120
CID19090
Chronopil
Chronopil (TN)
D008535
D08167
DB00351
 
EINECS 222-628-6
HSDB 3233
LS-118488
MGA
Megestrol (INN)
Megestrol Acetate
Megestrol [INN:BAN]
Megestrolo
Megestrolo [DCIT]
Megestrolum [INN-Latin]
Megestryl acetate
UNII-EA6LD1M70M
megestrol
19Contraceptives, OralPhase 33734
20Central Nervous System StimulantsPhase 31721
21Anti-Infective AgentsPhase 2, Phase 3, Phase 117220
22Appetite StimulantsPhase 358
23Antineoplastic Agents, HormonalPhase 34256
24AnestheticsPhase 37385
25Anesthetics, GeneralPhase 32274
26Anesthetics, IntravenousPhase 31943
27Analgesics, OpioidPhase 32304
28MitomycinsPhase 3219
29Antifungal AgentsPhase 2, Phase 3, Phase 13015
30AnalgesicsPhase 39358
31Nucleic Acid Synthesis InhibitorsPhase 3, Phase 1, Phase 23836
32PorfiromycinPhase 34
33Central Nervous System DepressantsPhase 310016
34Peripheral Nervous System AgentsPhase 318510
35Cholinergic AgentsPhase 33243
36Neurotransmitter AgentsPhase 314795
37Antibiotics, AntitubercularPhase 3, Phase 2, Phase 15971
38pancreatic polypeptidePhase 3, Phase 120
39Anti-Bacterial AgentsPhase 3, Phase 2, Phase 19140
40Liver ExtractsPhase 3, Phase 2, Phase 13572
41NarcoticsPhase 32709
42Psychotropic DrugsPhase 35501
43Histamine AntagonistsPhase 3826
44Antidepressive AgentsPhase 32367
45Antidepressive Agents, TricyclicPhase 3250
46
histaminePhase 390675614-87-8, 51-45-6774
Synonyms:
.beta.-Imidazolyl-4-ethylamine
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1avn
1qft
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-imidazol-5-yl)ethanamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-yl-Ethylamine
2-Imidazol-4-ylethylamine
2-[4-Imidazolyl]ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
5-Imidazoleethylamine
51-45-6
53290_FLUKA
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
BSPBio_001117
BSPBio_002124
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
Histamine
Histamine (DCF)
Histamine Base
Histamine [USAN]
Histamine, Free Base
Histaminum
 
Histaminum (TN)
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L-Histamin base
L-Histamine
L-histamine
L000292
LS-75835
Lopac-H-7250
Lopac0_000595
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
ST073926
STK346752
STOCK5S-55669
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
Spectrum_000845
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
[3H]histamine
b-Imidazolyl-4-ethylamine
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
beta-aminothethylglyoxaline
bmse000744
histamine
nchembio.87-comp54
nchembio714-comp1
47ColaNutraceuticalPhase 3, Phase 1, Phase 21768
48
Oxaliplatinapproved, investigationalPhase 2132261825-94-35310940, 9887054, 6857599, 43805, 6857599, 9887054
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
 
Oxalatoplatin
Oxalatoplatinum
Oxaliplatin
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
Oxaliplatino [Spanish]
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
oxaliplatin
49
AldesleukinapprovedPhase 238785898-30-2
Synonyms:
IL-2
Interleukin-2 precursor
 
Proleukin
T-cell growth factor
TCGF
50
CarboplatinapprovedPhase 1, Phase 2188541575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)

Interventional clinical trials:

(show top 50)    (show all 100)
idNameStatusNCT IDPhase
1Radiation Therapy and Chemotherapy in Treating Patients With Head and Neck CancerCompletedNCT00002507Phase 3
2Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
3Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck CancerCompletedNCT00090337Phase 3
4Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck CancerCompletedNCT00017511Phase 3
5Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck CancerCompletedNCT00002533Phase 2, Phase 3
6Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive TractCompletedNCT00765440Phase 3
7Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck CancerCompletedNCT00006799Phase 3
8Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without ChemotherapyActive, not recruitingNCT01156142Phase 3
9Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By SurgeryWithdrawnNCT00041171Phase 3
10A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary GlandsCompletedNCT00886132Phase 2
11Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and NeckCompletedNCT00581360Phase 2
12A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary GlandsCompletedNCT01678105Phase 2
13Study of RAD001 in Adenoid Cystic CarcinomaCompletedNCT01152840Phase 2
14Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and NeckCompletedNCT00077428Phase 2
15Dovitinib in Adenoid Cystic CarcinomaCompletedNCT01417143Phase 2
16Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland CancersCompletedNCT00095563Phase 2
17Gemcitabine in Treating Patients With Recurrent or Metastatic Adenoid Cystic Cancer of the Head and NeckCompletedNCT00017498Phase 2
18Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck CancerCompletedNCT00492089Phase 2
19Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerCompletedNCT00101348Phase 1, Phase 2
20Docetaxel in Treating Patients With Solid TumorsCompletedNCT00003565Phase 2
21Chemotherapy in Treating Patients With Solid TumorsCompletedNCT00003103Phase 1, Phase 2
22Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck CancerCompletedNCT00448552Phase 2
23Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid TumorsCompletedNCT00019331Phase 2
24Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid TumorCompletedNCT00021047Phase 1, Phase 2
25Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth CancerCompletedNCT00004901Phase 1, Phase 2
26Imatinib Mesylate in Treating Patients With Salivary Gland CancerCompletedNCT00045669Phase 2
27Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare DiseasesCompletedNCT00154388Phase 2
28Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung CancerCompletedNCT00021333Phase 2
29Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck CancerCompletedNCT00509665Phase 2
30Cisplatin or Carboplatin Combined With Gemcitabine in Treating Patients With Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland TumorCompletedNCT00079079Phase 2
31Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and NeckRecruitingNCT00180921Phase 2
32Adenoid Cystic Carcinoma, Erbitux, and Particle TherapyRecruitingNCT01192087Phase 1, Phase 2
33Testing Lenvatinib in Patients With Adenoid Cystic CarcinomaRecruitingNCT02780310Phase 2
34Intensity-Modulated or Proton Radiation Therapy for Sinonasal MalignancyRecruitingNCT01586767Phase 2
3518F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis TherapyRecruitingNCT01806675Phase 1, Phase 2
36External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain MetastasesRecruitingNCT00637637Phase 2
37Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic CarcinomaActive, not recruitingNCT02098538Phase 2
38Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic CarcinomaActive, not recruitingNCT01558661Phase 2
39Study of Dovitinib (TKI258) in Adenoid Cystic CarcinomaActive, not recruitingNCT01524692Phase 2
40Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic CarcinomaActive, not recruitingNCT01175980Phase 2
41Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst CarcinomaActive, not recruitingNCT01604772Phase 2
42Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland TumorsActive, not recruitingNCT00859937Phase 2
43Nelfinavir in Recurrent Adenoid Cystic Cancer of the Head and NeckActive, not recruitingNCT01065844Phase 2
44Combination Chemotherapy Plus Amifostine in Treating Patients With Metastatic or Unresectable CancerActive, not recruitingNCT00003657Phase 2
45Antineoplaston Therapy in Treating Patients With Advanced Head and Neck CancerActive, not recruitingNCT00003489Phase 2
46Trastuzumab in Treating Patients With Advanced Salivary Gland CancerActive, not recruitingNCT00004163Phase 2
47Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During SurgeryActive, not recruitingNCT00003744Phase 2
48Capecitabine and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Salivary Gland Cancer That Cannot Be Removed By SurgeryActive, not recruitingNCT00101075Phase 2
49Phase II Study of Pazopanib in Patients With Progressive Recurrent or Metastatic Salivary Gland CarcinomaActive, not recruitingNCT02393820Phase 2
50Iressa Study in Patients With Salivary Gland CancerActive, not recruitingNCT00509002Phase 2

Search NIH Clinical Center for Salivary Gland Adenoid Cystic Carcinoma


Cochrane evidence based reviews: carcinoma, adenoid cystic

Genetic Tests for Salivary Gland Adenoid Cystic Carcinoma

About this section

Anatomical Context for Salivary Gland Adenoid Cystic Carcinoma

About this section

MalaCards organs/tissues related to Salivary Gland Adenoid Cystic Carcinoma:

33
Salivary gland, Skin, Breast, Lymph node, Uterus, Trachea, Brain

Animal Models for Salivary Gland Adenoid Cystic Carcinoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Salivary Gland Adenoid Cystic Carcinoma:

38 (show all 21)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053828.7BCL2, KIT, NOS2, RUNX3, VEGFA
2MP:00053718.3CYLD, EN1, KIT, PGR, RUNX3, VEGFA
3MP:00028738.3CDH1, CYLD, EN1, KIT, PGR, VEGFA
4MP:00053818.1BCL2, CDH1, CYLD, KIT, NOS2, RUNX3
5MP:00053808.1CDH1, CTTN, EN1, KIT, PGR, VEGFA
6MP:00030127.8CDH1, CTTN, KIT, PCNA, PGR, RUNX3
7MP:00020067.7BCL2, CDH1, CYLD, KIT, NOS2, PGR
8MP:00053887.6AQP1, BCL2, CTTN, CYLD, KIT, NOS2
9MP:00053697.5BCL2, EN1, KIT, NOS2, PGR, RUNX3
10MP:00107717.0BCL2, CDH1, CYLD, EN1, KIT, NOS2
11MP:00053866.8AQP1, BCL2, CYLD, EN1, KIT, NOS2
12MP:00053846.4BCL2, CDH1, CTTN, CYLD, EN1, KIT
13MP:00053856.3AQP1, BCL2, CDH1, CTTN, EN1, KIT
14MP:00053766.3AQP1, BCL2, CDH1, CYLD, EN1, KIT
15MP:00053786.3AQP1, BCL2, CDH1, CTTN, CYLD, EN1
16MP:00053896.2AQP1, BCL2, CDH1, CTTN, EN1, KIT
17MP:00053796.2AQP1, BCL2, CDH1, CYLD, EN1, KIT
18MP:00053875.7BCL2, CDH1, CTTN, CYLD, EN1, KIT
19MP:00107685.5AQP1, BCL2, CDH1, CTTN, CYLD, EN1
20MP:00053975.3AQP1, BCL2, CTTN, CYLD, EN1, KIT

Publications for Salivary Gland Adenoid Cystic Carcinoma

About this section

Articles related to Salivary Gland Adenoid Cystic Carcinoma:

(show all 48)
idTitleAuthorsYear
1
Clinical utility gene card for: Trimethylaminuria - update 2014. (25335494)
2014
2
CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation. (24584857)
2014
3
Role of P14 and MGMT gene methylation in hepatocellular carcinomas: a meta-analysis. (25169493)
2014
4
Sectoral loss of myelin and axons in anterior ischemic optic neuropathy. (23528450)
2013
5
Traditional serrated adenoma of the colorectum: clinicopathologic implications and endoscopic findings of the precursor lesions. (24225759)
2013
6
Promotion of thermal analgesia and neuropeptidergic skin reinnervation by 4-methylcatechol in resiniferatoxin-induced neuropathy. (23906230)
2013
7
The clinical course over the first year of Whiplash Associated Disorders (WAD): pain-related disability predicts outcome in a mildly affected sample. (24359208)
2013
8
Plasmacytoma-like post-transplantation lymphoproliferative disease occurring in a cardiac allograft: a case report and review of the literature. (22711849)
2012
9
The Role of Multidetector CT in the Diagnosis of Retroperitoneal Fibrosis: Report of a Case. (23329957)
2012
10
Oral immunotherapy for egg allergy in children. (23050540)
2012
11
Intestinal atresia and ectopia in a bovine fetus. (20926733)
2011
12
Occurrence of BCR-ABL1-positive chronic myeloid leukemia following essential thrombocythemia. (21934297)
2011
13
Traumatic internal carotid artery dissection associated with playing soccer: a case report. (21935841)
2011
14
YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma. (21391238)
2011
15
Acquired amegakaryocytic thrombocytopenia: potential role of thrombopoietin receptor agonists. (21326159)
2010
16
Is baroreflex sensitivity really pathological in patients with somatization disorder? Comment on: Laederach-Hofmann et al. (2008). (19505528)
2009
17
A new cause of male infertility after cisplatin exposure: the effect of cisplatin on Y chromosomes. (18407334)
2009
18
Hereditary diffuse gastric cancer: surgery, surveillance and unanswered questions. (18684065)
2008
19
Cx30.2 can form heteromeric gap junction channels with other cardiac connexins. (18291099)
2008
20
Endochondral ossification: how cartilage is converted into bone in the developing skeleton. (17659995)
2008
21
P2X1 stimulation promotes thrombin receptor-mediated platelet aggregation. (16634759)
2006
22
Microsatellite instability and DNA mismatch repair deficiency testing in hereditary and sporadic gastrointestinal cancers. (15749237)
2005
23
Overexpression of dopa decarboxylase in peritoneal dissemination of gastric cancer and its potential as a novel marker for the detection of peritoneal micrometastases with real-time RT-PCR. (14760382)
2004
24
Correlation between UDP-glucuronosyltransferase genotypes and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone glucuronidation phenotype in human liver microsomes. (14871856)
2004
25
A novel mutation (Thr116Ile) in the presenilin 1 gene in a patient with early-onset Alzheimer's disease. (15272895)
2004
26
Treatment of lateral epicondylitis: where is the evidence? (15474386)
2004
27
Equilibrium interactions of corepressors and coactivators with agonist and antagonist complexes of glucocorticoid receptors. (15016838)
2004
28
Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. (15263088)
2004
29
The secondary alcohol and aglycone metabolites of doxorubicin alter metabolism of human erythrocytes. (14666248)
2003
30
Testis-specific expression of the nuclear form of phospholipid hydroperoxide glutathione peroxidase (PHGPx). (12751792)
2003
31
A promoter polymorphism in the monoamine oxidase A gene and its relationships to monoamine metabolite concentrations in CSF of healthy volunteers. (10867119)
2000
32
Human chemokine receptors CCR5, CCR3 and CCR2B share common polarity motif in the first extracellular loop with other human G-protein coupled receptors implications for HIV-1 coreceptor function. (10469138)
1999
33
Marie Unna congenital hypotrichosis: clinical description, histopathology, scanning electron microscopy of a previously unreported large pedigree. (10674378)
1999
34
Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. (9935237)
1999
35
Opioid mu receptors in caudate nucleus contribute to electroacupuncture and Sm I generating inhibition on nociceptive responses of Pf neurons]. (11972175)
1999
36
Renal tubular acidosis. (10456202)
1999
37
Primary localized amyloidosis of the urethra in a woman. (9666785)
1998
38
Granulocyte colony-stimulating factor enhances endotoxin-induced decrease in biliary excretion of the antibiotic cefoperazone in rats. (9736531)
1998
39
Case report: agranulocytosis induced by interferon-alpha therapy for chronic hepatitis C. (8985818)
1996
40
Virilizing adrenal ganglioneuroma containing Leydig cells. (8237234)
1993
41
Surfactant protein B: lipid interactions of synthetic peptides representing the amino-terminal amphipathic domain. (1871144)
1991
42
Treatment of discoid lupus erythematosus. (2684876)
1989
43
Patients with hemophilia B (Christmas disease) who have anti-factor IX: genetic heterogeneity. (3411190)
1988
44
Class II genes of the human major histocompatibility complex. Evolution of the DP region as deduced from nucleotide sequences of the four genes. (3036829)
1987
45
Influence of several chemical reagents on lymphocytic choriomeningitis and Tacaribe viruses. (3962180)
1986
46
X-linked recessive ichthyosis vulgaris: rapid identification by lipoprotein electrophoresis. (6682648)
1983
47
Bilateral acute dacryocystitis in a premature infant. (739349)
1978
48
Female hermaphroditism without virilization. (13465085)
1957

Variations for Salivary Gland Adenoid Cystic Carcinoma

About this section

Cosmic variations for Salivary Gland Adenoid Cystic Carcinoma:

7 (show top 50)    (show all 936)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
1COSM43878TP53salivary gland,NS,carcinoma,adenoid cystic carcinoma4
2COSM43878TP53salivary gland,NS,carcinoma,adenoid cystic carcinoma4
3COSM43614TP53salivary gland,NS,carcinoma,adenoid cystic carcinoma4
4COSM43614TP53salivary gland,NS,carcinoma,adenoid cystic carcinoma4
5COSM43920TP53skin,face,carcinoma,NS3
6COSM43931TP53salivary gland,major,carcinoma,NS3
7COSM43920TP53skin,face,carcinoma,NS3
8COSM43878TP53salivary gland,major,carcinoma,NS3
9COSM43878TP53salivary gland,major,carcinoma,adenoid cystic carcinoma3
10COSM43931TP53salivary gland,major,carcinoma,NS3
11COSM43878TP53salivary gland,major,carcinoma,NS3
12COSM44097TP53skin,face,carcinoma,NS3
13COSM44119TP53salivary gland,major,carcinoma,NS3
14COSM44119TP53salivary gland,major,carcinoma,NS3
15COSM44097TP53skin,face,carcinoma,NS3
16COSM43742TP53skin,face,carcinoma,NS3
17COSM44097TP53skin,face,carcinoma,NS3
18COSM44097TP53skin,face,carcinoma,NS3
19COSM43700TP53skin,face,carcinoma,NS3
20COSM43596TP53skin,face,carcinoma,NS3
21COSM43596TP53skin,face,carcinoma,NS3
22COSM43588TP53skin,face,carcinoma,NS3
23COSM43588TP53skin,face,carcinoma,NS3
24COSM43582TP53skin,face,carcinoma,NS3
25COSM43582TP53skin,face,carcinoma,NS3
26COSM43632TP53salivary gland,NS,carcinoma,adenocarcinoma3
27COSM43632TP53salivary gland,NS,carcinoma,adenocarcinoma3
28COSM44227TP53skin,face,carcinoma,NS3
29COSM43700TP53skin,face,carcinoma,NS3
30COSM43680TP53salivary gland,major,carcinoma,NS3
31COSM43680TP53salivary gland,major,carcinoma,NS3
32COSM43665TP53skin,face,carcinoma,NS3
33COSM43665TP53skin,face,carcinoma,NS3
34COSM43742TP53skin,face,carcinoma,NS3
35COSM44241TP53skin,face,carcinoma,NS3
36COSM10705TP53skin,face,carcinoma,NS3
37COSM10705TP53skin,face,carcinoma,NS3
38COSM10705TP53skin,face,carcinoma,NS3
39COSM10705TP53skin,face,carcinoma,NS3
40COSM10705TP53skin,face,carcinoma,NS3
41COSM10705TP53skin,face,carcinoma,NS3
42COSM10992TP53skin,face,carcinoma,NS3
43COSM10992TP53skin,face,carcinoma,NS3
44COSM44068TP53skin,face,carcinoma,NS3
45COSM44068TP53skin,face,carcinoma,NS3
46COSM11449TP53skin,face,carcinoma,NS3
47COSM11449TP53skin,face,carcinoma,NS3
48COSM44436TP53skin,face,carcinoma,NS3
49COSM44436TP53skin,face,carcinoma,NS3
50COSM10705TP53skin,face,carcinoma,NS3

Expression for genes affiliated with Salivary Gland Adenoid Cystic Carcinoma

About this section
Search GEO for disease gene expression data for Salivary Gland Adenoid Cystic Carcinoma.

Pathways for genes affiliated with Salivary Gland Adenoid Cystic Carcinoma

About this section

GO Terms for genes affiliated with Salivary Gland Adenoid Cystic Carcinoma

About this section

Biological processes related to Salivary Gland Adenoid Cystic Carcinoma according to GeneCards Suite gene sharing:

(show all 8)
idNameGO IDScoreTop Affiliating Genes
1melanocyte differentiationGO:003031810.2BCL2, KIT
2regulation of developmental pigmentationGO:004807010.2BCL2, KIT
3T cell differentiationGO:003021710.1BCL2, KIT
4nucleotide-binding domain, leucine rich repeat containing receptor signaling pathwayGO:00358729.9BCL2, CYLD
5pigmentationGO:00434739.9BCL2, KIT
6dopaminergic neuron differentiationGO:00715429.7EN1, VEGFA
7growthGO:00400079.6BCL2, VEGFA
8ovarian follicle developmentGO:00015419.1BCL2, KIT, VEGFA

Sources for Salivary Gland Adenoid Cystic Carcinoma

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet